» Articles » PMID: 12769445

Increasing Fecal Butyrate in Ulcerative Colitis Patients by Diet: Controlled Pilot Study

Overview
Specialty Gastroenterology
Date 2003 May 29
PMID 12769445
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Topical butyrate has been shown to be effective in the treatment of ulcerative colitis (UC). Butyrate is derived from colonic fermentation of dietary fiber, and our aim was to study whether UC patients could safely increase the fecal butyrate level by dietary means. We enrolled 22 patients with quiescent UC (mean age, 44 years; 45% women; median time from last relapse, 1 year) in a controlled pilot trial lasting 3 months. The patients were instructed to add 60 g oat bran (corresponding to 20 g dietary fiber) to the daily diet, mainly as bread slices. Fecal short-chain fatty acids (SCFAs) including butyrate, disease activity, and gastrointestinal symptoms were recorded every 4 weeks. During the oat bran intervention the fecal butyrate concentration increased by 36% at 4 weeks (from 11 +/- 2 (mean +/- SEM) to 15 +/- 2 micromol/g feces) (p < 0.01). The mean butyrate concentration over the entire test period was 14 +/- 1 micromol/g feces (p < 0.05). Remaining fecal SCFA levels were unchanged. No patient showed signs of colitis relapse. Unlike controls, the patients showed no increase in gastrointestinal complaints during the trial. Yet patients reporting abdominal pain and reflux complaints at entry showed significant improvement at 12 weeks that returned to baseline 3 months later. This pilot study shows that patients with quiescent UC can safely take a diet rich in oat bran specifically to increase the fecal butyrate level. This may have clinical implications and warrants studies of the long-term benefits of using oat bran in the maintenance therapy in UC.

Citing Articles

Gut Microbiome as Potential Therapeutics in Multiple Sclerosis.

Zhu W, Dykstra K, Zhang L, Xia Z Curr Treat Options Neurol. 2025; 23(11).

PMID: 39877812 PMC: 11774507. DOI: 10.1007/s11940-021-00693-1.


Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective.

Qin L, Lv W Nutr J. 2025; 24(1):12.

PMID: 39849464 PMC: 11755847. DOI: 10.1186/s12937-025-01075-y.


Correlation between the Quantity and Type of Dietary Fiber with the Activity in Mexican Patients with Ulcerative Colitis (UC).

Martinez-Vazquez S, Corral-Ceballos J, Yamamoto-Furusho J Nutrients. 2024; 16(18).

PMID: 39339798 PMC: 11435422. DOI: 10.3390/nu16183198.


Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis.

Zhang S, Nie Q, Sun Y, Zuo S, Chen C, Li S Microbiome. 2024; 12(1):177.

PMID: 39300532 PMC: 11414225. DOI: 10.1186/s40168-024-01896-9.


Maximizing Treatment Options for IBD through Drug Repurposing.

Barjasteh A, Al-Asady A, Latifi H, Al Okla S, Al-Nazwani N, Avan A Curr Pharm Des. 2024; 30(32):2538-2549.

PMID: 39039672 DOI: 10.2174/0113816128318032240702045822.